LITTLETON, Colo., March 4 /PRNewswire-FirstCall/ -- Chay Enterprises, Inc. is pleased to announce today that the company has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals will trade on the NASDAQ BB under the symbol CHYE. “We have asked FINRA to change our symbol,” said Don Wingerter, Ampio Pharmaceuticals’ CEO, “and expect to be trading under our new symbol in less than thirty days.”
Dr. David Bar-Or, Ampio Pharmaceuticals’ founder and Chief Scientific Officer, stated, “I have been working for over 30 years on finding solutions to important diseases that can impact an aging population. My role as the Director of Trauma Research at two major Colorado Level One Trauma Centers has given me the unique opportunity to study a variety of diseases in both clinical and research settings.”
Safe Harbor Statement
Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.
CONTACT: Investors, Jens Dalsgaard of Redwood Consultants, LLC,
+1-415-884-0348, for Ampio Pharmaceuticals
Web site: http://www.ampiopharma.com/
